Zenas BioPharma (ZBIO) Gains from Investment Securities (2024 - 2026)

Zenas BioPharma's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $33130.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 71.23% year-over-year to $33130.0; the TTM figure through Mar 2026 stood at $33130.0 (down 71.23% YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
• Gains from Investment Securities was $33130.0 for Q1 2026 at Zenas BioPharma, down from $1.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $2.7 million in Q3 2025 to a low of $33130.0 in Q1 2026.
• Historically, Gains from Investment Securities has averaged $902997.2 across 3 years, with a median of $755550.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities gained 5.5% in 2025, then sank 71.23% in 2026.
• A 3-year view of Gains from Investment Securities shows it stood at $1.0 million in 2024, then advanced by 5.5% to $1.1 million in 2025, then tumbled by 96.86% to $33130.0 in 2026.
• The last three Gains from Investment Securities figures came in at $33130.0 (Q1 2026), $1.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.